Clinical trial · Observational
The Role of POLE Mutation in High Risk Endometrial Cancer.
NCT07114653CI-TRIAL-00093389recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The actual role of POLE mutations in high-risk endometrial cancer is undetermined. The main question it aims to answer is: What is the prevalence of POLE mutations in high-risk endometrial cancer case? What is the impact of POLE mutations in real world high-risk endometrial cancer case?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Neoplasms | Endometrial Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- endometrial cancer
- description
- high-risk for reurrence of endometrial cancer.
Primary outcomes (1)
- measure
- Prevalence of POLE mutation in high risk endometrial cancer
- timeFrame
- 2 years
- description
- The prevalence of POLE mutations in women with high-risk for recurrent endometrial cancer
Secondary outcomes (1)
- measure
- The impact of POLE on overall survival
- timeFrame
- 5 years
- description
- The impact of POLE on overall survival, compared with the other TCGA groups
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * women with high-risk for recurrent endometrial cancer Exclusion Criteria: * Nil
References
Publications (0)
Data not yet available
No reference posted for this study.